Literature DB >> 27312156

Imbalanced immune homeostasis in immune thrombocytopenia.

Karina Yazdanbakhsh1.   

Abstract

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder resulting from low platelet counts caused by inadequate production as well as increased destruction by autoimmune mechanisms. As with other autoimmune disorders, chronic ITP is characterized by perturbations of immune homeostasis with hyperactivated effector cells as well as defective regulatory arm of the adaptive immune system, which will be reviewed here. Interestingly, some ITP treatments are associated with restoring the regulatory imbalance, although it remains unclear whether the immune system is redirected to a state of tolerance once treatment is discontinued. Understanding the mechanisms that result in breakdown of immune homeostasis in ITP will help to identify novel pathways for restoring tolerance and inhibiting effector cell responses. This information can then be translated into developing therapies for averting autoimmunity not only in ITP but also many autoimmune disorders.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immune dysregulation; Immune thrombocytopenia; Thrombopoietin

Mesh:

Year:  2016        PMID: 27312156      PMCID: PMC5321649          DOI: 10.1053/j.seminhematol.2016.04.006

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  47 in total

1.  Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation.

Authors:  Meggan Czapiga; Allan D Kirk; Julie Lekstrom-Himes
Journal:  Exp Hematol       Date:  2004-02       Impact factor: 3.084

2.  Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia.

Authors:  Jiang Cao; Chong Chen; Li Li; Zeng Ling-yu; Li Zhen-yu; Yan Zhi-ling; Chen Wei; Cheng Hai; Wei Sang; Xu Kai-lin
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

3.  Reduced expression of transforming growth factor-β1 and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP).

Authors:  Jiaan-Der Wang; Te-Kau Chang; Heng-Kuei Lin; Fang-Liang Huang; Chau-Jong Wang; Huei-Jane Lee
Journal:  Pediatr Blood Cancer       Date:  2011-06-30       Impact factor: 3.167

4.  Flow cytometric evaluation of platelet activation in chronic autoimmune thrombocytopenia.

Authors:  Simon Panzer; Lisa Höcker; Rainer Vormittag; Miriam Rieger; Daniela Koren; Daniela Dunkler; Ingrid Pabinger
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

5.  The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia.

Authors:  Andreia Maria Camargos Rocha; Cláudia Souza; Gifone Aguiar Rocha; Fabrício Freire de Melo; Nelma Cristina Diogo Clementino; Marília Campos Abreu Marino; Adriana Bozzi; Maria Luiza Silva; Olindo Assis Martins Filho; Dulciene Maria Magalhães Queiroz
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

Review 6.  A brief history of T cell help to B cells.

Authors:  Shane Crotty
Journal:  Nat Rev Immunol       Date:  2015-02-13       Impact factor: 53.106

7.  Activated platelets rapidly up-regulate CD40L expression and can effectively mature and activate autologous ex vivo differentiated DC.

Authors:  Ja Martinson; J Bae; H-G Klingemann; Yk Tam
Journal:  Cytotherapy       Date:  2004       Impact factor: 5.414

8.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

9.  Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling.

Authors:  Stefanie Eyerich; Kilian Eyerich; Davide Pennino; Teresa Carbone; Francesca Nasorri; Sabatino Pallotta; Francesca Cianfarani; Teresa Odorisio; Claudia Traidl-Hoffmann; Heidrun Behrendt; Stephen R Durham; Carsten B Schmidt-Weber; Andrea Cavani
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

Review 10.  Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy.

Authors:  Jagadeesh Bayry; Sophie Sibéril; Frédéric Triebel; David F Tough; Srini V Kaveri
Journal:  Drug Discov Today       Date:  2007-06-27       Impact factor: 7.851

View more
  4 in total

1.  Platelet-specific antibodies and differences in their expression in childhood immune thrombocytopenic purpura predicts clinical progression.

Authors:  Lingling Fu; Jie Ma; Zhengping Cheng; Hao Gu; Jingyao Ma; Runhui Wu
Journal:  Pediatr Investig       Date:  2019-01-08

Review 2.  Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy.

Authors:  David Buchbinder; Diane Nugent; Loan Hsieh
Journal:  Drug Des Devel Ther       Date:  2017-03-30       Impact factor: 4.162

3.  Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the major human platelet autoantigen glycoprotein IIb/IIIa in HLA-transgenic mice.

Authors:  Lindsay S Hall; Charlotte S Lennon; Andrew M Hall; Stanislaw J Urbaniak; Mark A Vickers; Robert N Barker
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

Review 4.  The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases.

Authors:  Maura Argenziano; Chiara Tortora; Giulia Bellini; Alessandra Di Paola; Francesca Punzo; Francesca Rossi
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.